SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat

Girerd, Nicolas; Zannad, Faı̈ez

doi:10.1111/joim.13620

Cited by 6 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In clinical heart failure situations, SGLT2 inhibitors are generally well-tolerated and efficacious medications. [9]…”

Section: Discussionmentioning

confidence: 99%

SGLT2-Inhibitors - significant role in Heart Failure treatment

Wielgus,

Bator,

Pawłowska

et al. 2024

J Educ Health Sport

View full text Add to dashboard Cite

Heart failure (HF), which has a high morbidity and mortality rate, is nevertheless a common and crippling ailment, especially in older populations. The complicated pathophysiology of heart failure (HF), which includes oxidative stress, endothelial dysfunction, fibrosis, and inflammation, is frequently not sufficiently treated despite advances in medication. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become a key treatment for HF in patients with varying left ventricular ejection fractions (LVEF). SGLT2 inhibitors have been shown in recent clinical trials to considerably lower hospitalization rates for heart failure, cardiovascular mortality, and all-cause mortality. The mechanisms of SGLT2 inhibitors, such as better ventricular loading, increased heart metabolic efficiency, and decreased inflammation and necrosis, are covered in this review. Additionally, we provide an overview of four important clinical trials—DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER—highlighting their effectiveness in lowering unfavourable cardiovascular outcomes for patients with heart failure who have preserved (HFpEF), slightly reduced (HFmrEF), or reduced (HFrEF). The results validate the need for SGLT2 inhibitors in all-inclusive HF treatment plans by highlighting their adaptability and safety in a range of clinical contexts.

show abstract

“…In clinical heart failure situations, SGLT2 inhibitors are generally well-tolerated and efficacious medications. [9]…”

Section: Discussionmentioning

confidence: 99%

SGLT2-Inhibitors - significant role in Heart Failure treatment

Wielgus,

Bator,

Pawłowska

et al. 2024

J Educ Health Sport

View full text Add to dashboard Cite

show abstract

“…Aunque algunos ensayos clínicos incluyeron pacientes con insuficiencia cardiaca aguda (ICA), la mayoría de ellos se realizaron con IC crónica estable, si bien ésto no debe impedir su prescripción desde los SU. Así, la evidencia actual indica que los iSGLT2 deben iniciarse en todo el amplio espectro de FE y función renal en pacientes con IC con y sin diabetes, desde cualquier ámbito de atención y de forma precoz 10,11 .…”

Section: Introductionunclassified

Sodium-glucose co-transporter 2 inhibitors: their role in heart failure management in emergency departments

Llorens

2024

Rev Esp Urg Emerg

View full text Add to dashboard Cite

Los inhibidores del cotransportador de sodio-glucosa (iSGLT2) son eficaces en la insuficiencia cardiaca (IC) con cualquier rango de la fracción de eyección (FE). Han demostrado reducción de ingresos por IC, arritmias, visitas a urgencias, mortalidad cardiovascular y mortalidad por otras causas. La evidencia actual indica que los iSGLT2 deben ser iniciados de forma precoz en los pacientes con IC independientemente de su FE o de la presencia o no de diabetes mellitus (DM). En este trabajo revisamos los beneficios de los iSGLT2 tanto en la IC con FE reducida, con FE ligeramente reducida y conservada, quedando patente que los efectos de reducción de la morbimortalidad se inician de forma precoz tras su introducción. En conjunto, la evidencia actual apoya su uso tanto en IC aguda y crónica iniciado desde urgencias, con buena tolerancia y sin necesidad de titulación.

show abstract

Recurrence of left ventricular systolic dysfunction and its risk factors in heart failure with improved ejection fraction patients receiving guideline-directed medical therapy: A trajectory analysis based on echocardiography

Fu,

Yang,

Wang

et al. 2024

International Journal of Cardiology

View full text Add to dashboard Cite

SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat

Abstract: Girerd N, Zannad F. SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat.

Cited by 6 publications

References 45 publications

SGLT2-Inhibitors - significant role in Heart Failure treatment

SGLT2-Inhibitors - significant role in Heart Failure treatment

Sodium-glucose co-transporter 2 inhibitors: their role in heart failure management in emergency departments

Recurrence of left ventricular systolic dysfunction and its risk factors in heart failure with improved ejection fraction patients receiving guideline-directed medical therapy: A trajectory analysis based on echocardiography

Contact Info

Product

Resources

About